Literature DB >> 8596320

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.

G Monaghan1, M Ryan, R Seddon, R Hume, B Burchell.   

Abstract

BACKGROUND: The genetic basis of Gilbert's syndrome is ill-defined. This common mild hyperbilirubinaemia sometimes presents as an intermittent jaundice. A reduced hepatic bilirubin UPD- glucuronosyltransferase (UGT) is associated with this syndrome. We have examined variation in the gene encoding the UGT1*1 enzyme and serum bilirubin levels in a Scottish population.
METHODS: Blood was collected from 12 patients with confirmed or suspected Gilbert's syndrome, from 6 members of a family with 4 Gilbert members, and from 77 non-smoking, alcohol-free, drug-free volunteers recruited from the staff of a teaching hospital in Dundee. Polymerase chain reaction amplification was used to examine sequence variation of the promoter upstream of the UGT1*1 exon I. Genotypes were assigned as follows: 6/6 (homozygous for a common allele bearing the sequence [TA](6)TAA), 7/7 (homozygous for a rarer allele with the sequence [TA](7)TAA), and 6/7 (heterozygous with one of each allele).
FINDINGS: Individuals in the population with the 7/7 genotype had significantly higher bilirubin concentrations than those who had the 6/7 or 6/6 genotype. 14 volunteers underwent a 24 h fasting test to see if they had Gilbert's syndrome, and all four positives had the 7/7 genotype. One confirmed Gilbert's patient, two recurrent jaundice patients (with suspected Gilbert's syndrome), and nine clinically diagnosed cases had the 7/7 genotype. Segregation of the 7/7 genotype with the Gilbert phenotype was also demonstrated in the family with four affected members. The frequency of the 7/7 genotype in this eastern Scottish population was 10-13%.
INTERPRETATION: In a healthy population there was an association between variation in bilirubin concentration and a mutation within the gene encoding the enzyme bilirubin UGT. This and other findings suggest the existence of a mild and a more severe form of Gilbert's syndrome, depending on whether the gene defect lies in the promoter sequence upstream of UGT1*I exon I, as here (mild), or in the coding sequence (severe) of the gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8596320     DOI: 10.1016/s0140-6736(96)91273-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  118 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study.

Authors:  Jing-Ping Lin; L Adrienne Cupples; Peter W F Wilson; Nancy Heard-Costa; Christopher J O'Donnell
Journal:  Am J Hum Genet       Date:  2003-02-28       Impact factor: 11.025

3.  Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Authors:  Nathan R Jones; Dongxiao Sun; Willard M Freeman; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-06-01       Impact factor: 4.030

4.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

5.  Intractable neonatal jaundice due to hereditary spherocytosis and Gilbert's syndrome.

Authors:  Abdul Qader Tahir Ismail; Anjum Gandhi; Nagui El-Shimy
Journal:  BMJ Case Rep       Date:  2011-07-28

6.  Clinical (nonforensic) application of ethyl glucuronide measurement: are we ready?

Authors:  Peter Jatlow; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2010-04-05       Impact factor: 3.455

7.  Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Frank Z Stanczyk; Kim C Westerlind; Katherine M Newton; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-28       Impact factor: 4.292

Review 8.  Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Authors:  Thomas I Peng Soh; Wei Peng Yong; Federico Innocenti
Journal:  Clin Chem Lab Med       Date:  2011-09-28       Impact factor: 3.694

Review 9.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Authors:  Christine M Walko; Howard McLeod
Journal:  Nat Clin Pract Oncol       Date:  2009-01-27

10.  Mechanism of indinavir-induced hyperbilirubinemia.

Authors:  S D Zucker; X Qin; S D Rouster; F Yu; R M Green; P Keshavan; J Feinberg; K E Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.